Drug intelligence / Profile preview

18F-FB-RMSH-1

Development stage
Preclinical
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration
Intravenous
01

Overview

18F-FB-RMSH-1 is a radiofluorinated metallopeptide developed as a molecular probe for positron emission tomography (PET) imaging of tumors expressing the melanocortin 1 receptor (MC1R), particularly malignant melanoma. It is a specific isomer of the rhenium-cyclized alpha-melanocyte-stimulating hormone (alpha-MSH) analog, Ac-d-Lys-ReCCMSH(Arg(11)), labeled with fluorine-18 via N-succinimidyl-4-18F-fluorobenzoate (18F-SFB). In preclinical studies, 18F-FB-RMSH-1 demonstrated high binding affinity to MC1R and superior in vivo performance compared to its isomer 18F-FB-RMSH-2, characterized by higher tumor uptake and significantly lower accumulation in the kidneys and liver. This profile makes it a promising candidate for the non-invasive detection and monitoring of MC1R-positive malignancies.

Other names
18F-FB-Ac-d-Lys-ReCCMSH(Arg(11))18F-FB-RMSH118F-labeled metallopeptide RMSH-1
02

Targets

MC1R (Melanocortin Type 1 Receptor)

Beyond the preview

Go deeper on 18F-FB-RMSH-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-FB-RMSH-1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call